Hematogenous Donor Cell Routing Pathway After Transamniotic Stem Cell Therapy

Sarah A. Tracy; Alexander V. Chalphin; Ina Kycia; Christopher Chan; Adam Finkelstein; David Zurakowski; Dario O. Fauza

doi:10.1089/scd.2020.0012

Hematogenous Donor Cell Routing Pathway After Transamniotic Stem Cell Therapy

Stem Cells and Development ◽

10.1089/scd.2020.0012 ◽

2020 ◽

Vol 29 (12) ◽

pp. 755-760

Author(s):

Sarah A. Tracy ◽

Alexander V. Chalphin ◽

Ina Kycia ◽

Christopher Chan ◽

Adam Finkelstein ◽

...

Keyword(s):

Stem Cell ◽

Cell Therapy ◽

Stem Cell Therapy ◽

Donor Cell

Download Full-text

Transamniotic Stem Cell Therapy for Experimental Congenital Diaphragmatic Hernia: Structural, Transcriptional, and Cell Kinetics Analyses in the Nitrofen Model

Fetal Diagnosis and Therapy ◽

10.1159/000515277 ◽

2021 ◽

pp. 1-11

Author(s):

Alexander V. Chalphin ◽

Stefanie P. Lazow ◽

Daniel F. Labuz ◽

Sarah A. Tracy ◽

Ina Kycia ◽

...

Keyword(s):

Stem Cell ◽

Cell Therapy ◽

Congenital Diaphragmatic Hernia ◽

Stem Cell Therapy ◽

Diaphragmatic Hernia ◽

Cell Kinetics ◽

Donor Cell ◽

Wald Test ◽

Saline Group ◽

Pulmonary Vasculature

Purpose: We examined select pulmonary effects and donor cell kinetics after transamniotic stem cell therapy (TRASCET) in a model of congenital diaphragmatic hernia (CDH). Methods: Pregnant dams (n = 58) received nitrofen on gestational day 9.5 (E9) to induce fetal CDH. Fetuses (n = 681) were divided into 4 groups: untreated (n = 99) and 3 groups receiving volume-matched intra-amniotic injections on E17 of either saline (n = 142), luciferase-labeled amniotic fluid-derived mesenchymal stem cells (afMSCs; n = 299), or acellular recombinant luciferase (n = 141). Pulmonary morphometry, quantitative gene expression of pulmonary vascular tone mediators, or screening for labeled afMSCs were performed at term (E22). Statistical comparisons were by Mann-Whitney U-test, nested ANOVA, and Wald test. Results: TRASCET led to significant downregulation of endothelial nitric oxide synthase and endothelin receptor-A expressions compared to both untreated and saline groups (both p < 0.001). TRASCET also led to a significant decrease in arteriole wall thickness compared to the untreated group (p < 0.001) but not the saline group (p = 0.180). Donor afMSCs were identified in the bone marrow and umbilical cord (p = 0.035 and 0.015, respectively, vs. plain luciferase controls). Conclusions: The effects of TRASCET in experimental CDH appear to be centered on the pulmonary vasculature and to derive from circulating donor cells.

Download Full-text

Method Categorization of Stem Cell Therapy for Degenerative Osteoarthritis of the Knee: A Review

International Journal of Molecular Sciences ◽

10.3390/ijms222413323 ◽

2021 ◽

Vol 22 (24) ◽

pp. 13323

Author(s):

Jae Sun Lee ◽

Dong Woo Shim ◽

Kyung-Yil Kang ◽

Dong-Sik Chae ◽

Woo-Suk Lee

Keyword(s):

Stem Cell ◽

Cell Therapy ◽

Stem Cell Therapy ◽

Donor Cell ◽

Cartilage Defects ◽

Osteoarthritis Of The Knee ◽

Tibial Osteotomy ◽

Treatment Methods ◽

Mesenchymal Stem Cell Therapy ◽

Stem Cell Treatment

Current clinical applications of mesenchymal stem cell therapy for osteoarthritis lack consistency because there are no established criteria for clinical processes. We aimed to systematically organize stem cell treatment methods by reviewing the literature. The treatment methods used in 27 clinical trials were examined and reviewed. The clinical processes were separated into seven categories: cell donor, cell source, cell preparation, delivery methods, lesion preparation, concomitant procedures, and evaluation. Stem cell donors were sub-classified as autologous and allogeneic, and stem cell sources included bone marrow, adipose tissue, peripheral blood, synovium, placenta, and umbilical cord. Mesenchymal stem cells can be prepared by the expansion or isolation process and attached directly to cartilage defects using matrices or injected into joints under arthroscopic observation. The lesion preparation category can be divided into three subcategories: chondroplasty, microfracture, and subchondral drilling. The concomitant procedure category describes adjuvant surgery, such as high tibial osteotomy. Classification codes were assigned for each subcategory to provide a useful and convenient method for organizing documents associated with stem cell treatment. This classification system will help researchers choose more unified treatment methods, which will facilitate the efficient comparison and verification of future clinical outcomes of stem cell therapy for osteoarthritis.

Download Full-text